Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio

SUTRO BIOPHARMA, INC.

Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.
Three Class I directors elected: Heidi Hunter, Jon Wigginton, Michael Dybbs for three-year terms.
Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 2025 with 99.1% for.
Non-binding advisory vote on named executive officer compensation passed with 42.99M for.
All proposals passed at June 6, 2025 annual meeting; broker non-votes ranged from 12.5M on director elections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.